Patient demographics and clinical characteristics (N = 66)
| . | No. of patients . |
|---|---|
| Sex | |
| Female | 27 (41) |
| Male | 39 (59) |
| Age, median (range), y | 64 (38-79) |
| ISS stage | |
| I | 21 (35) |
| II/III | 39 (65) |
| Unknown | 6 |
| Cytogenetic abnormalities | |
| t(11;14) | 9 (14) |
| t(4;14) | 5 (8) |
| del(17p) | 15 (23) |
| del(13q) | 30 (45) |
| Hyperdiploid | 30 (45) |
| No. of prior lines of therapy,* median (range) | 3 (1-13) |
| Stem cell transplant | 39 (59) |
| Prior bortezomib/refractory | 53 (80)/26 (39) |
| Prior lenalidomide/refractory | 48 (73)/35 (53) |
| Refractory to last line of therapy | 40 (61) |
| . | No. of patients . |
|---|---|
| Sex | |
| Female | 27 (41) |
| Male | 39 (59) |
| Age, median (range), y | 64 (38-79) |
| ISS stage | |
| I | 21 (35) |
| II/III | 39 (65) |
| Unknown | 6 |
| Cytogenetic abnormalities | |
| t(11;14) | 9 (14) |
| t(4;14) | 5 (8) |
| del(17p) | 15 (23) |
| del(13q) | 30 (45) |
| Hyperdiploid | 30 (45) |
| No. of prior lines of therapy,* median (range) | 3 (1-13) |
| Stem cell transplant | 39 (59) |
| Prior bortezomib/refractory | 53 (80)/26 (39) |
| Prior lenalidomide/refractory | 48 (73)/35 (53) |
| Refractory to last line of therapy | 40 (61) |
Data are presented as n (%) of patients unless otherwise indicated.
ISS, International Staging System.
Percentage of patients who were refractory to each prior therapy is based on all enrolled patients.